Combined versus sequential hormonal replacement therapy: A double-blind, placebo-controlled study on quality of life-related outcome measures

被引:40
作者
Bech, P [1 ]
Munk-Jensen, N
Obel, EB
Ulrich, LG
Eiken, P
Nielsen, SP
机构
[1] Frederiksborg Gen Hosp, Inst Psychiat, DK-3400 Hillerod, Denmark
[2] Frederiksborg Gen Hosp, Dept Clin Physiol, DK-3400 Hillerod, Denmark
[3] Horsholm Hosp, Dept Gynaecol, Horsholm, Denmark
[4] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
关键词
hormonal replacement therapy; oestradiol; norethisterone acetate; quality of life; menopause;
D O I
10.1159/000012289
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: To compare combined and sequential hormonal replacement therapies to each other as well as placebo in patients suffering from the postmenopausal syndrome. Clinical outcomes were measured concerning both the specific postmenopausal symptoms (using the Kupperman scale) and health or well-being dimensions (using subscales of the General Health Questionnaire and specific depression and anxiety scales). Methods: A prospective randomized double-blind study over 12 months of 105 normal early postmenopausal women in the setting of a general hospital. Results: Both hormone replacement therapies were superior to placebo on the Kupperman scale (sweating, hot flushing, myalgia and vertigo). The psychic symptoms on the Kupperman scale were psychometrically invalid. However, psychic symptoms as measured by the Beck Depression Inventory and the General Health Questionnaire were significantly improved by the hormonal replacement therapies. No differences were observed when combined therapy was compared to sequential therapy. Conclusion: One-year treatment with hormonal replacement therapy is superior to placebo in measuring the somatic and psychic symptoms of the menopausal syndrome. No differences were found in this respect be:tween combined and sequential replacement therapy.
引用
收藏
页码:259 / 265
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 1956, NONPARAMETRIC STAT
[2]  
[Anonymous], 1980, International classification of impairments, disabilities and handicaps
[4]   The WHO (Ten) well-being index: Validation in diabetes [J].
Bech, P ;
Gudex, C ;
Johansen, KS .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 1996, 65 (04) :183-190
[5]  
BECH P, 1988, ACTA PSYCHIAT SCAND, V78, P45
[6]   QUALITY-OF-LIFE MEASUREMENTS FOR PATIENTS TAKING WHICH DRUGS - THE CLINICAL PCASEE PERSPECTIVE [J].
BECH, P .
PHARMACOECONOMICS, 1995, 7 (02) :141-151
[7]  
BECH P, 1981, Acta Psychiatrica Scandinavica Supplementum, V64, P1
[8]  
BECH P, 1990, METHODOLOGY EVALUATI
[9]  
BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165
[10]  
Coope J, 1981, J R Coll Gen Pract, V31, P134